Zilovertamab vedotin
- Generic Name
- Zilovertamab vedotin
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2376463-48-6
- Unique Ingredient Identifier
- IZY9ZSI6FI
- Background
Zilovertamab vedotin is an Antibody-drug conjugate (ADC) comprising an anti-ROR1 monoclonal antibody (UC-961), a proteolytically cleavable maleimidocaproyl-valine-citrulline-para-aminobenzoate linker (mc-vc-PAB), and a monomethyl auristatin E (MMAE) cytotoxin.
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Phase 2
Recruiting
- Conditions
- Diffuse Large B-Cell LymphomaDLBCL
- Interventions
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 290
- Registration Number
- NCT05139017
- Locations
- 🇹🇭
Chulalongkorn University ( Site 0402), Pathumwan, Krung Thep Maha Nakhon, Thailand
🇺🇸Bass Medical Group ( Site 0166), Walnut Creek, California, United States
🇺🇸Innovative Clinical Research Institute ( Site 0122), Whittier, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath